drugset / Trial / NCT01722513

Efficacy and Safety of Alprostadil Prevent Contrast Induced Nephropathy

NCT01722513

Phase 4 Unknown 150 enrolled Shanghai 10th People's Hospital
NaSingle-groupSingle-blindPrevention

Summary

The aim of this prospective, randomized, controlled study is to investigate the effect of pretreatment with intravenous Alprostadil on the incidence of CIN in a high-risk population of patients with both type 2 diabetes mellitus (T2DM) and CKD undergoing coronary angiography, and evaluate the influence of such potential benefit on short-term outcome.

Timeline

Start
2012-11
Primary completion
2013-11
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Alprostadil Unknown 40 ug Intravenous